Company Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally.
The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS; and TOFIDENCE, a tocilizumab biosimilar referencing ACTEMRA.
It offers RITUXAN to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies.
In addition, the company is developing products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, and biosimilars.
Biogen Inc. has collaboration and license agreements with Merz Therapeutics; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; and Sage Therapeutics, Inc., as well as collaborations with Fujirebio to identify and develop biomarkers for tau pathology in the brain and Stoke Therapeutics, Inc. for the development and commercialization of zorevunersen, a disease modifying medicine for the treatment of Dravet syndrome.
The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
| Country | United States |
| Founded | 1978 |
| IPO Date | Sep 16, 1991 |
| Industry | Drug Manufacturers - General |
| Sector | Healthcare |
| Employees | 7,605 |
| CEO | Christopher Viehbacher |
Contact Details
Address: 225 Binney Street Cambridge, Massachusetts 02142 United States | |
| Phone | 617 679 2000 |
| Website | biogen.com |
Stock Details
| Ticker Symbol | BIIB |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000875045 |
| CUSIP Number | 09062X103 |
| ISIN Number | US09062X1037 |
| Employer ID | 33-0112644 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Christopher A. Viehbacher | President, Chief Executive Officer and Director |
| Michael R. McDonnell CPA | Executive Vice President and Chief Financial Officer |
| Nicole Murphy | Head of Pharmaceutical Operations and Technology |
| Susan H. Alexander Esq. | Executive Vice President and Chief Legal Officer |
| Rachid Izzar | Head of Global Product Strategy and Commercialization |
| Robin C. Kramer | Senior Vice President and Chief Accounting Officer |
| Tim Power M.B.A., Ph.D. | Head of Investor Relations |
| Natacha Gassenbach | Chief Communication Officer and Head of Corporate Affairs |
| Adam Keeney Ph.D. | Executive Vice President and Head of Corporate Development |
| Dr. Ginger Gregory Ph.D. | Executive Vice President and Chief Human Resources Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 12, 2025 | 10-K | Annual Report |
| Feb 12, 2025 | 8-K | Current Report |
| Jan 15, 2025 | 8-K | Current Report |
| Dec 9, 2024 | 144 | Filing |
| Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 4, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Oct 30, 2024 | 8-K | Current Report |
| Oct 30, 2024 | 10-Q | Quarterly Report |
| Oct 30, 2024 | 8-K | Current Report |
| Oct 16, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |